# US 2020/0392233 A1 · Alk7 binding proteins and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392233 A1
- Document ID: US20200392233A1
- Status: Published application
- Kind: A1
- Application number: 16/757,959
- Filed: 2018-10-25
- Published: 2020-12-17
- Earliest claimed: 2017-10-25
- Assignees: Acceleron Pharma Inc.; Adimab, LLC
- Applicants: Acceleron Pharma Inc.; Adimab, LLC
- Inventors: Ravindra Kumar; Roselyne Castonguay; Dianne Sako; Jonathan Belk; Nathan J. Sharkey
- Web page: https://patentgrep.com/patent/US20200392233A1

## CPC

- A61P 3/04: Anorexiants; Antiobesity agents
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.

## Claims

### Claim 1

An Activin Receptor-Like Kinase 7 (ALK7)-binding protein that specifically binds at least one primary epitope of an ALK7 protein, wherein the at least one primary epitope is essentially the same as an epitope selected from SEQ ID NOs:310, 313, and 317.

### Claim 2 (depends on 1)

The ALK7-binding protein of claim 1, further specifically binds at least one conformational epitope of an ALK7 protein, wherein the at least one conformational epitope is essentially the same as an epitope selected from SEQ ID NOs:311, 312, 314, 315, 316, 318, and 319.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The ALK7-binding protein of claim 1, comprising a set of CDRs: VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2 and VL-CDR3, wherein the CDRs are from a heavy chain variable region (VH) and a light chain variable region (VL) pair selected from:
(a) (i) a VH sequence of SEQ ID NO:117, and
(ii) a VL sequence of SEQ ID NO:124;
(b) (i) a VH sequence of SEQ ID NO:105, and
(ii) a VL sequence of SEQ ID NO:110;
(c) (i) a VH sequence of SEQ ID NO:128, and
(ii) a VL sequence of SEQ ID NO:135;
(d) (i) a VH sequence of SEQ ID NO:140, and
(ii) a VL sequence of SEQ ID NO:148;
(e) (i) a VH sequence of SEQ ID NO:91, and
(ii) a VL sequence of SEQ ID NO:98;
(f) (i) a VH sequence of SEQ ID NO:4, and
(ii) a VL sequence of SEQ ID NO:13;
(g) (i) a VH sequence of SEQ ID NO:152, and
(ii) a VL sequence of SEQ ID NO:98;
(h) (i) a VH sequence of SEQ ID NO:159, and
(ii) a VL sequence of SEQ ID NO:110;
(i) (i) a VH sequence of SEQ ID NO:165, and
(ii) a VL sequence of SEQ ID NO:171;
(j) (i) a VH sequence of SEQ ID NO:22, and
(ii) a VL sequence of SEQ ID NO:31;
(k) (i) a VH sequence of SEQ ID NO:40, and
(ii) a VL sequence of SEQ ID NO:49; and
(l) (i) a VH sequence of SEQ ID NO:58, and
(ii) a VL sequence of SEQ ID NO:67,
wherein the protein binds to ALK7.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The ALK7-binding protein of claim 1, comprising a set of CDRs in which:
(a) (i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:114;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:115;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:116;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:121;
(v) VL-CDR2 comprises the amino acid sequence of SEQ ID NO:122; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO:123;
(b) (i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:102;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:103;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:104;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:107;
(v) VL-CDR2 comprises the amino acid sequence of SEQ ID NO:108; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO:109;
(c) (i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:125;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:126;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:127;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:132;
(v) VL-CDR2 comprises the amino acid sequence of SEQ ID NO:133; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO:134;
(d) (i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:137;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:138;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:139;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:145;
(v) VL-CDR2 comprises the amino acid sequence of SEQ ID NO:146; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO:147;
(e) (i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:88;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:89;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:90;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:95;
(v) VL-CDR2 comprises the amino acid sequence of SEQ ID NO:96; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO:97;
(g) (i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:37;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:56;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:90;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:95;
(v) VL-CDR2 comprises the amino acid sequence of SEQ ID NO:96; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO:97;
(h) (i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:156;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:157;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:104;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:107;
(v) VL-CDR2 comprises the amino acid sequence of SEQ ID NO:108; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO:109;
(h) (i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:1;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:163;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:164;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:167;
(v) VL-CDR2 comprises the amino acid sequence of SEQ ID NO:168; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO:169;
(i) (i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:1;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:2;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:3;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:10;
(v) VL-CDR2 comprises the amino acid sequence of SEQ ID NO:11; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO:12;
(j) (i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:19;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:20;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:21;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:28;
(v) VL-CDR2 comprises the amino acid sequence of SEQ ID NO:29; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO:30;
(k) (i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:37;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:38;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:39;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:46;
(v) VL-CDR2 comprises the amino acid sequence of SEQ ID NO:47; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO:48; or
(l) (i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO:55;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO:56;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:57;
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO:64;
(v) VL-CDR2 comprises the amino acid sequence of SEQ ID NO:65; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO:66,
wherein the protein binds ALK7.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The ALK7-binding protein of claim 1, wherein the VH and VL pair is selected from:
(a) a VH sequence of SEQ ID NO:117 and a VL sequence of SEQ ID NO:124;
(b) a VH sequence of SEQ ID NO:105 and a VL sequence of SEQ ID NO:110;
(c) a VH sequence of SEQ ID NO:128 and a VL sequence of SEQ ID NO:135;
(d) a VH sequence of SEQ ID NO:140 and a VL sequence of SEQ ID NO:148;
(e) a VH sequence of SEQ ID NO:91 and a VL sequence of SEQ ID NO:98;
(f) a VH sequence of SEQ ID NO:152 and a VL sequence of SEQ ID NO:98;
(g) a VH sequence of SEQ ID NO:159 and a VL sequence of SEQ ID NO:110;
(h) a VH sequence of SEQ ID NO:165, and a VL sequence of SEQ ID NO:171;
(i) a VH sequence of SEQ ID NO:4 and a VL sequence of SEQ ID NO:13;
(j) a VH sequence of SEQ ID NO:22 and a VL sequence of SEQ ID NO:31;
(k) a VH sequence of SEQ ID NO:40, and a VL sequence of SEQ ID NO:49; and
(l) a VH sequence of SEQ ID NO:58 and a VL sequence of SEQ ID NO:67,
wherein the protein binds ALK7.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The ALK7-binding protein of claim 1, comprising a HC and LC pair selected from:
(a) (i) a HC having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:190 or 320, and
(ii) a LC having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:191 or 322; and
(b) (i) a HC having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:192 or 324, and
(ii) a LC having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:193 or 326,
wherein the protein binds ALK7.

### Claim 11 (depends on 1)

The ALK7-binding protein of claim 1, comprising a HC and LC pair selected from:
(a) (i) a HC having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:194 or 328, and
(ii) a LC having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:191 or 322; and
(b) (i) a HC having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:195 or 330, and
(ii) a LC having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:193 or 326,
wherein the protein binds ALK7.

### Claim 12 (depends on 1)

The ALK7-binding protein of claim 1, comprising a HC and LC pair selected from:
(a) (i) a HC having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:196 or 332, and
(ii) a LC having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:191 or 322; and
(b) (i) a HC having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:197 or 334, and
(ii) a LC having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO:193 or 326,
wherein the protein binds ALK7.

### Claim 13

An ALK7-binding protein that binds an overlapping epitope on ALK7, wherein the overlapping epitope shares at least one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or more identical amino acid residues with the epitopes set forth in SEQ ID NOs:310-319.

### Claim 14 (depends on 1)

An ALK7-binding protein which cross-blocks or competes for binding to ALK7 with the ALK7-binding protein according to claim 1.

### Claim at position 15

15-33. (canceled)

### Claim 34 (depends on 1)

An nucleic acid molecule or set of nucleic acid molecules encoding an ALK7-binding protein according to claim 1.

### Claim 35

(canceled)

### Claim 36 (depends on 34)

A polynucleotide or cDNA molecule sufficient for use as a hybridization probe, PCR primer or sequencing primer that is a fragment of the nucleic acid molecule or set of nucleic acid molecules of claim 34, or its complement.

### Claim 37

(canceled)

### Claim 38 (depends on 34)

A vector comprising the nucleic acid molecule according to claim 34.

### Claim 39 (depends on 34)

A host cell comprising the nucleic acid molecule of claim 34.

### Claim at position 22

40-41. (canceled)

### Claim 42 (depends on 1)

A method of making the ALK7-binding protein of claim 1, comprising culturing a host cell under suitable conditions for producing the ALK7-binding protein.

### Claim 43

(canceled)

### Claim 44 (depends on 42)

An ALK7-binding protein produced using the method of claim 42.

### Claim 45 (depends on 1)

A pharmaceutical composition comprising an ALK7-binding protein according to claim 1 and a pharmaceutically acceptable carrier.

### Claim at position 27

46-50. (canceled)

### Claim 51 (depends on 1)

A method for treating and/or ameliorating a disease or condition associated with ALK7 expression or elevated ALK7-mediated signaling in a subject, comprising administering to a subject in need thereof an effective amount of a composition comprising an ALK7-binding protein of claim 1.

### Claim at position 29

52-53. (canceled)

### Claim 54 (depends on 1)

A method of reducing ALK7 activity in a subject comprising administering an effective amount of an ALK7-binding protein according to claim 1.

### Claim 55 (depends on 1)

A method for treating and/or ameliorating Prader-Willi syndrome, comprising administering to a subject in need thereof an effective amount of a composition comprising an ALK7-binding protein of claim 1.
